Antibodies and the Blood-Brain Barrier

Therapeutic Monoclonal Antibodies: From Bench to Clinic

Volumn , Issue , 2009, Pages 483-502

  Jones, Angela R ^a   Shusta, Eric V ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Antibodies and blood brain barrier; Intrinsic antibody transport at BBB; Noninvasive modes for improving antibody delivery

Indexed keywords

EID: 84891003599     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470485408.ch21     Document Type: Chapter

References (136)

1. Abbott, N.J. 2002. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200(6):629-638.
2. Abbott, N.J., L. Ronnback, and E. Hansson. 2006. Astrocyte-endothelial interactions at the blood-brain barrier. Nature Rev. Neurosci. 7(1):41-53.
3. Abulrob, A., H. Sprong, P. Henegouwen, and D. Stanimirovic. 2005. The blood-brain barrier transmigrating single domain antibody: Mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem. 95(4):1201-1214.
4. Alyautdin, R.N., V.E. Petrov, K. Langer, A. Berthold, D.A. Kharkevich, and J. Kreuter. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 1997; 14(3):325-328.
5. Ambruosi, A., A.S. Khalansky, H. Yamamoto, S.E. Gelperina, D.J. Begley, and J. Kreuter. 2006. Biodistribution of polysorbate 80-coated doxorubicin-loaded [C-14]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J. Drug Target. 14(2):97-105.
6. Ambruosi, A., H. Yamamoto, and J. Kreuter. 2005. Body distribution of polysorbate-80 and doxorubicin-loaded [C-14]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats. J. Drug Target. 13(10):535-542.
7. Arthur, F.E., R.R. Shivers, and P.D. Bowman. 1987. Astrocyte-mediated induction of tight junctions in brain capillary endothelium: An efficient in vitro model. Dev. Brain Res. 36(1):155-159.
8. Bard, F., C. Cannon, R. Barbour, et al. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6(8):916-919.
9. Bickel, U., T. Yoshikawa, and W.M. Pardridge. 1993. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 10(2-3):205-245.
10. Bickel, U., T. Yoshikawa, and W.M. Pardridge. 2001. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 46(1-3):247-279.
11. Black, K.L., T. Cloughesy, S.C. Huang, et al. 1997. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J. Neurosurg. 86(4):603-609.
12. Boado, R.J., H. Tsukamoto, and W.M. Pardridge. 1998. Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J. Pharm. Sci. 87(11):1308-1315.
13. Boado, R.J., Y. Zhang, and W.M. Pardridge. 2007. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol. Bioeng. 97(6):1376-1386.
14. Boado, R.J., Y. Zhang, C.F. Xia, and W.M. Pardridge. 2007a. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and A-beta fibril disaggregation. Bioconjug. Chem. 18(2):447-455.
15. Boado, R.J., Y.F. Zhang, Y. Zhang, and W.M. Pardridge. 2007b. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioeng. 96(2):381-391.
16. Boado, R.J., Y. Zhang, Y.F. Zhang, C.F. Xia, Y.T. Wang, W.M. Pardridge. 2008. Genetic engineering of a lysoso-mal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol. Bioeng. 99(2):475-484.
17. Brightman, M.W., T.S. Reese, and N. Feder. 1970. Assessment with the electron microscope of the permeability to peroxidase of cerebral endothelium and epithelium in mice and sharks. In Capillary Permeability, ed. C. Crone and N.A. Lassen. Copenhagen: Munksgaard.
18. Brown, V.I., and M.I. Greene. 1991. Molecular and cellular mechanisms of receptor-mediated endocytosis. DNA CellBiol. 10(6):399-409.
19. Cameron, P.L., C.D. Liu, D.K. Smart, S.T. Hantus, J.R. Fick, and R.S. Cameron. 2002. Caveolin-1 expression is maintained in rat and human astroglioma cell lines. Glia 37(3):275-290.
20. Cerletti, A., J. Drewe, G. Fricker, A.N. Eberle, and J. Huwyler. 2000. Endocytosis and transcytosis of an immuno-liposome-based brain drug delivery system. J. Drug Target. 8(6):435-436.
21. Cestelli, A., C. Catania, S. D'Agostino, et al. 2001. Functional feature of a novel model of blood brain barrier: Studies on permeation of test compounds. J. Control. Release 76(1-2):139-147.
22. Chinta, S.J., and J.K. Andersen. 2005. Dopaminergic neurons. Int. J. Biochem. Cell Biol. 37(5):942-946.
23. Coloma, M.J., H.J. Lee, A. Kurihara, et al. 2000. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. 17(3):266-274.
24. Cordon-Cardo, C., J.P. Obrien, D. Casals, et al. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86(2):695-698.
25. Cortez-Retamozo, V., N. Backmann, P.D. Senter, et al. 2004. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 64(8):2853-2857.
26. Davson, H., K. Welch, and M.B. Segal. 1987. Secretion of the cerebrospinal fluid. In The Physiology and Pathophysiology of the Cerebrospinal Fluid, ed. E.A. Neuwelt. London: Churchill Livingstone.
27. Deane, R., A. Sagare, K. Hamm, et al. 2005. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci. 25(50):11495-11503.
28. DeMattos, R.B., K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul, and D.M. Holtzman. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98(15):8850-8855.
29. Demeule, M., J. Poirier, J. Jodoin, et al. 2002. High transcytosis of melanotransferrin (P97) across the blood brain barrier. J. Neurochem. 83(4):924-933.
30. Dodel, R.C., H. Hampel, and Y.S. Du. 2003. Immunotherapy for Alzheimer's disease. Lancet Neurol. 2(4):215-220.
31. Dohgu, S., F. Takata, A. Yamauchi, et al. 2005. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production. Brain Res. 1038(2):208-215.
32. Duffy, K.R., and W.M. Pardridge. 1987. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res. 420(1):32-38.
33. Elan Corporation. N.D. Elan: Alzheimer's Research (http://www.elan.com/research_development/Alzheimers/Default.asp. Accessed April 21, 2008.)
34. Endicott, J.A., and V. Ling. 1989. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58:137-171.
35. Falagas, M.E., I.A. Bliziotis, and V.H. Tam. 2007. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: A systematic review of the available evidence. Int. J. Antimicrob. Agents 29(1):9-25.
36. Fleischhack, G., U. Jaehde, and U. Bode. 2005. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin. Pharmacokinet. 44(1):1-31.
37. Friden, P.M., T.S. Olson, R. Obar, L.R. Walus, and S.D. Putney. 1996. Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor. J. Pharmacol. Exp. Ther. 278(3):1491-1498.
38. Friden, P.M., L.R. Walus, G.F. Musso, M.A. Taylor, B. Malfroy, and R.M. Starzyk. 1991. Antitransferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 88(11):4771-4775.
39. Gaillard, P., A. Brink, and A.G. de Boer. 2005. Diphtheriatoxin receptor-targeted brain drug delivery. Int. Congres. Series 1277:185-198.
40. Gaillard, P.J., C.C. Visser, and A.G. de Boer. 2005. Targeted delivery across the blood-brain barrier. Expert Opin. Drug Deliv. 2(2):299-309.
41. Gao, K., and X. Jiang. 2006. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 310(1-2):213-219.
42. Ge, S.J., L. Song, and J.S. Pachter. 2005. Where is the blood-brain barrier. . really? J. Neurosci. Res. 79(4):421-427.
43. Gerber, D.E., and J. Laterra. 2007. Emerging monoclonal antibody therapies for malignant gliomas. Expert Opin. Investig. Drugs 16(4):477-494.
44. Giometto, B., F. Bozza, V. Argentiero, et al. 1990. Transferrin receptors in rat central nervous system. An immuno-cytochemical study. J. Neurol. Sci. 98(1):81-90.
45. Golden, P.L., T.J. Maccagnan, and W.M. Pardridge. 1997. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J. Clin. Invest. 99(1):14-18.
46. Gulyaev, A.E., S.E. Gelperina, I.N. Skidan, A.S. Antropov, G.Y. Kivman, and J. Kreuter. 1999. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16(10):1564-1569.
47. Haavik, J., and K. Toska. 1998. Tyrosine hydroxylase and Parkinson's disease. Mol. Neurobiol. 16(3):285-309.
48. Havrankova, J., M. Brownstein, and J. Roth. 1981. Insulin and insulin receptors in rodent brain. Diabetologia 20 (Suppl 1):268-273.
49. Hebert, L.E., P.A. Scherr, J.L. Bienias, D.A. Bennett, and D.A. Evans. 2003. Alzheimer disease in the U.S. population: Prevalence estimates using the 2000 census. Arch. Neurol. 60(8):1119-1122.
50. Holliger, P., and P.J. Hudson. 2005. Engineered antibody fragments and the rise of single domains. Nature Biotechnol. 23(9):1126-1136.
51. Huwyler, J., D.F. Wu, and W.M. Pardridge. 1996. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U.S.A. 93(24):14164-14169.
52. Huwyler, J., J. Yang, and W.M. Pardridge. 1997. Receptor mediated delivery of daunomycin using immuno-liposomes: Pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther. 282(3):1541-1546.
53. Hwang, W.Y., and J. Foote. 2005. Immunogenicity of engineered antibodies. Methods 36(1):3-10.
54. Jefferies, W.A., M.R. Brandon, S.V. Hunt, A.F. Williams, K.C. Gatter, and D.Y. Mason. 1984. Transferrin receptor on endothelium of brain capillaries. Nature 312(5990):162-163.
55. Jones, A.R., and E.V. Shusta. 2007. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 24(9):1759-1771.
56. Kang, Y.S., U. Bickel, and W.M. Pardridge. 1994. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Drug Metab. Dispos. 22(1):99-105.
57. Kemper, E.M., W. Boogerd, I. Thuis, J.H. Beijnen, and O. van Tellingen. 2004. Modulation of the blood-brain barrier in oncology: Therapeutic opportunities for the treatment of brain tumours? Cancer Treat. Rev. 30(5):415-423.
58. Kordower, J.H., V. Charles, R. Bayer, et al. 1994. Intravenous administration of a transferrin receptor antibody nerve growth-factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. Proc. Natl. Acad. Sci. U.S.A. 91(19):9077-9080.
59. Kratz, F., and U. Beyer. 1998. Serum proteins as drug carriers of anticancer agents: A review. Drug Deliv. 5(4):281-299.
60. Kreuter, J., D. Shamenkov, V. Petrov, et al. 2002. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. 10(4):317-325.
61. Kroll, R.A., and E.A. Neuwelt. 1998. Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. Neurosurgery. 42(5):1083-1099.
62. Kroll, R.A., M.A. Pagel, L.L. Muldoon, S. Roman-Goldstein, S.A. Fiamengo, and E.A. Neuwelt. 1998. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: A comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery 43(4):879-886.
63. Laske, D.W., R.J. Youle, and E.H. Oldfield. 1997. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med. 3(12):1362-1368.
64. Lee, H.J., B. Engelhardt, J. Lesley, U. Bickel, and W.M. Pardridge. 2000. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther. 292(3):1048-1052.
65. Mak, M., L. Fung, J.F. Strasser, and W.M. Saltzman. 1995. Distribution of drugs following controlled delivery to the brain interstitium. J. Neurooncol. 26(2):91-102.
66. Marchi, N., L. Angelov, T. Masaryk, et al. 2007. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 48(4):732-742.
67. Mash, D.C., J. Pablo, B.E. Buck, J. Sanchezramos, and W.J. Weiner. 1991. Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice. Exp. Neurol. 114(1):73-81.
68. McAllister, L.D., N.D. Doolittle, P.E. Guastadisegni, et al. 2000. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46(1):51-60.
69. Mellouli, E., Z. Arrouji, M. Debre, and M. Bejaoui. 2003. Successful treatment of Echovirus 27 meningoencepha-litis in agammaglobulinaemia with intraventricular injection of gammaglobulin. A case report. Arch. Pediatr. 10(2):130-133.
70. Minino, A.M., M.P. Heron, S.L. Murphy, and K.D. Kochanek. 2007. Deaths: Final Data for 2004. National Vital Statistics Reports, Vol 55. Hyattsville, MD: National Center for Health Statistics.
71. Moos, T., and E.H. Morgan. 2000. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol. Neurobiol. 20(1):77-95.
72. Morrison, P.F., D.W. Laske, H. Bobo, E.H. Oldfield, and R.L. Dedrick. 1994. High-flow microinfusion: Tissue penetration and pharmacodynamics. Am. J. Physiol. 266(1):R292-R305.
73. Morrison, S.L., M.J. Johnson, L.A. Herzenberg, and V.T. Oi. 1984. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U.S.A. 81(21):6851-6855.
74. Muruganandam, A., J. Tanha, S. Narang, and D. Stanimirovic. 2002. Selection of phage-displayed llama singledomain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 16(2):240-242.
75. National Institute of Neurological Disorders and Stroke. 2005. NINDS Overview (April 15, 2005; http://www. ninds.nih.gov/about_ninds/ninds_overview.htm. AccessedApril 10, 2008).
76. Neuwelt, E.A., P.A. Barnett, D.D. Bigner, and E.P. Frenkel. 1982. Effects of adrenal-cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: The factor of the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 79(14):4420-4423.
77. Nicoll, J.A.R., D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R.O. Weller. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nature Med. 9(4):448-452.
78. Orgogozo, J.M., S. Gilman, J.F. Dartigues, et al. 2003. Subacute meningoencephalitis in a subset of patients with AD after A beta 42 immunization. Neurology 61(1):46-54.
79. Pan, W.H., A.J. Kastin, T.C. Zankel, P. van Kerkhof, T. Terasaki, and G.J. Bu. 2004. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J. Cell. Sci. 117(21):5071-5078.
80. Pardridge, W.M. 1991. Peptide Drug Delivery to the Brain. New York: Raven Press.
81. Pardridge, W.M. 2001. Brain Drug Targeting: The Future of Brain Drug Development. Cambridge, UK: Cambridge University Press.
82. Pardridge, W.M. 2002. Drug and gene targeting to the brain with molecular Trojan horses. Nature Rev. DrugDiscov. 1(2):131-139.
83. Pardridge, W.M., J. Eisenberg, and J. Yang. 1987. Human blood-brain barrier transferrin receptor. Metabolism 36(9):892-895.
84. Pardridge, W.M., Y.S. Kang, J.L. Buciak, and J. Yang. 1995a. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier. Pharm. Res. 12(6):807-816.
85. Pardridge, W.M., Y.S. Kang, J. Yang, and J.L. Buciak. 1995b. Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization. J. Pharm. Sci. 84(8):943-948.
86. Pardridge, W.M., J. Yang, J. Buciak, and W.W. Tourtellotte. 1989. Human brain microvascular DR-antigen. J. Neurosci. Res. 23(3):337-341.
87. Patel, S.J., W.R. Shapiro, D.W. Laske, et al. 2005. Safety and feasibility of convection-enhanced delivery of cotara for the treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery 56(6):1243-1252.
88. Penichet, M.L., Y.S. Kang, W.M. Pardridge, S.L. Morrison, and S.U. Shin. 1999. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: Initial applications in anti-HIV antisense drug delivery to the brain. J. Immunol. 163(8):4421-4426.
89. Pissarra, N. 2004. Changes in the business of culture. Nature Biotechnol. 22:1355-1356.
90. Poduslo, J.F., and G.L. Curran. 1994. Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers. Mol. Brain Res. 23(1-2):157-162.
91. Poduslo, J.F., and G.L. Curran. 1996. Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J. Neurochem. 66(4):1599-1609.
92. Poduslo, J.F., and G.L. Curran. 2001. Amyloidbetapeptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport 12(15):3197-3200.
93. Poduslo, J.F., G.L. Curran, and C.T. Berg. 1994. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. U.S.A. 91(12):5705-5709.
94. Poduslo, J.F., G.L. Curran, B. Sanyal, and D.J. Selkoe. 1999. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol. Dis. 6(3):190-199.
95. Qian, Z.M., H.Y. Li, H.Z. Sun, and K. Ho. 2002. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54(4):561-587.
96. Ramsauer, M., D. Krause, and R. Dermietzel. 2002. Angiogenesis of the blood-brain barrier in vitro and the function of cerebral pericytes. FASEB J. 16(8):1274-1276.
97. Raub, T.J., S.L. Kuentzel, and G.A. Sawada. 1992. Permeability of bovine brain microvessel endothelial cells in vitro: Barrier tightening by a factor released from astroglioma cells. Exp. Cell. Res. 199(2):330-340.
98. Roopenian, D.C., and S. Akilesh. 2007. FcRn: The neonatal Fc receptor comes of age. Nature Rev. Immunol. 7(9):715-725.
99. Rothberg, K.G., J.E. Heuser, W.C. Donzell, Y.S. Ying, J.R. Glenney, and R.G.W. Anderson. 1992. Caveolin, a protein-component of caveolae membrane coats. Cell 68(4):673-682.
100. Rubin, L.L., D.E. Hall, S. Porter, et al. 1991. A cell culture model of the blood-brain barrier. J. Cell Biol. 115(6):1725-1735.
101. Saerens, D., M. Pellis, R. Loris, et al. 2005. Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J. Mol. Biol. 352(3):597-607.
102. Sampson, J.H., L.E. Crotty, S. Lee, et al. 2000. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl. Acad. Sci. U.S.A. 97(13):7503-7508.
103. Schenk, D., R. Barbour, W. Dunn, et al. 1999. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 400(6740):173-177.
104. Schlachetzki, F., C.N. Zhu, and W.M. Pardridge. 2002. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J. Neurochem. 81(1):203-206.
105. Schroder, U., and B.A. Sabel. 1996. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res. 710(1-2):121-124.
106. Shi, N., R.J. Boado, and W.M. Pardridge. 2000. Antisense imaging of gene expression in the brain in vivo. Proc. Natl. Acad. Sci. U.S.A. 97(26):14709-14714.
107. Shi, N.Y., R.J. Boado, and W.M. Pardridge. 2001. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. 18(8):1091-1095.
108. Shi, N.Y., Y. Zhang, C.N. Zhu, R.J. Boado, and W.M. Pardridge. 2001. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. U.S.A. 98(22):12754-12759.
109. Smith, M.W., and M. Gumbleton. 2006. Endocytosis at the blood-brain barrier: From basic understanding to drug delivery strategies. J. Drug Target. 14(4):191-214.
110. Solomon, B., R. Koppel, D. Frankel, and E. HananAharon. 1997. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U.S.A. 94(8):4109-4112.
111. Song, B.W., H.V. Vinters, D.F. Wu, and W.M. Pardridge. 2002. Enhanced neuroprotective effects ofbasic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J. Pharmacol. Exp. Ther. 301(2):605-610.
112. Steiniger, S.C.J., J. Kreuter, A.S. Khalansky, et al. 2004. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109(5):759-767.
113. Sugawara, I., H. Hamada, T. Tsuruo, and S. Mori. 1990. Specialized localization of P-glycoprotein recognized by Mrk 16 monoclonal antibody in endothelial cells of the brain and the spinal cord. Jpn. J. Cancer Res. 81(8):727-730.
114. Suzuki, T., D.F. Wu, F. Schlachetzki, J.Y. Li, R.J. Boado, and W.M. Pardridge. 2004. Imaging endogenous gene expression in brain cancer in vivo with In-111-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J. Nuclear Med. 45(10):1766-1775.
115. Tao-Cheng, J.H., Z. Nagy, and M.W. Brightman. 1987. Tightjunctions of brain endothelium in vitro are enhanced by astroglia. J. Neurosci. 7(10):3293-3299.
116. Triguero, D., J.L. Buciak, and W.M. Pardridge. 1991. Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate. J. Pharmacol. Exp. Ther. 258(1):186-192.
117. Triguero, D., J.B. Buciak, J. Yang, and W.M. Pardridge. 1989. Blood-brain barrier transport of cationized immunoglobulin G enhanced delivery compared to native protein. Proc. Natl. Acad. Sci. U.S.A. 86(12): 4761-4765.
118. Tsuji, A., T. Terasaki, Y. Takabatake, et al. 1992. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial-cells. Life Sci. 51(18):1427-1437.
119. Tunkel, A.R., B.J. Hartman, S.L. Kaplan, et al. 2004. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. 39(9):1267-1284.
120. Ullrich, A., J.R. Bell, E.Y. Chen, et al. 1985. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313(6005):756-761.
121. Unterberg, A., Wahl, M., and A. Baethmann. 1984. Effects of bradykinin on permeability and diameter of pial vessels in vivo. J. Cereb. Blood Flow Metab. 4(4):574-585.
122. Urayama, A., J.H. Grubb, W.S. Sly, and W.A. Banks. 2004. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 101(34):12658-12663.
123. Wang, X.X., Y.K. Cho, and E.V. Shusta. 2007. Mining a yeast library for brain endothelial cell-binding antibodies. Nature Methods 4(2):143-145.
124. Xia, C.F., Y. Zhang, Y. Zhang, R.J. Boado, and W.M. Pardridge. 2007. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm. Res. 24(12):2309-2316.
125. Yan, Q., C. Matheson, J. Sun, M.J. Radeke, S.C. Feinstein, and J.A. Miller. 1994. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp. Neurol. 127(1):23-36.
126. Yang, W.L., R.F. Barth, G. Wu, et al. 2005. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin. Cancer Res. 11(1):341-350.
127. Zhang, Y., F. Calon, C.N. Zhu, R.J. Boado, and W.M. Pardridge. 2003. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene Ther. 14(1):1-12.
128. Zhang, Y., and W.M. Pardridge. 2001a. Mediated efflux of IgGmoleculesfrombraintoblood across the blood-brain barrier. J. Neuroimmunol. 114(1-2):168-172.
129. Zhang, Y., and W.M. Pardridge. 2001b. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 32(6):1378-1383.
130. Zhang, Y., and W.M. Pardridge. 2006. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res. 1111(1):227-229.
131. Zhang, Y., F. Schlachetzki, J.Y. Li, R.J. Boado, and W.M. Pardridge. 2003. Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol. Vis. 9:465-472.
132. Zhang, Y., F. Schlachetzki, and W.M. Pardridge. 2003. Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther. 7(1):11-18.
133. Zhang, Y., F. Schlachetzki, Y.F. Zhang, R.J. Boado, and W.M. Pardridge. 2004a. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum. Gene Ther. 15(4):339-350.
134. Zhang, Y., Y.F. Zhang, J. Bryant, A. Charles, R.J. Boado, and W.M. Pardridge. 2004b. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10(11):3667-3677.
135. Zhang, Y., C.N. Zhu, and W.M. Pardridge. 2002. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. 6(1):67-72.
136. Zlokovic, B.V., C.L. Martel, E. Matsubara, et al. 1996. Glycoprotein 330/megalin: Probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl. Acad. Sci. U.S.A. 93(9):4229-4234.